Bendamustine Treatment before CAR T-Cell Therapy May Be Detrimental
Vall d'Hebron Institute of Oncology
CAR T-cell therapy recipients with refractory lymphoma showed poorer treatment outcomes when treated with bendamustine
Articles by Vall d'Hebron Institute of Oncology
VIGex Could Guide Patient Selection for Personalized Immunotherapy
Vall d'Hebron Institute of Oncology
Prediction tool classifies solid tumors based on inflammation status, thereby triaging cases that will benefit the most
Novel Protein Inhibitor Shows Antitumor Activity in Patients with NHL
Vall d'Hebron Institute of Oncology
Monotherapy with new PRMT5 inhibitor well tolerated with low toxicity in adults with B cell non-Hodgkin lymphomas
Pioneering Cell Therapies for Non-Responders to Current Immunotherapies
Vall d'Hebron Institute of Oncology
Killer T cells identified in blood that can hone in on mutations uniquely expressed in cancer cells pave the way for an alternative and personalized therapeutic avenue